Morgan Stanley raised the firm’s price target on Eli Lilly (LLY) to $1,135 from $1,133 and keeps an Overweight rating on the shares. Year-to-date, large cap pharma and biotech companies have both underperformed given the macro environment, while multiple areas of policy uncertainty remain, including drug pricing dynamics, tariff and transfer pricing exposure, and FDA staffing changes, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- UBS Reiterates Buy Rating on Eli Lilly Stock (LLY) as Weight-Loss Drug Sales Accelerate
- Eli Lilly’s Remternetug Study: A Potential Game-Changer in Drug Delivery
- Eli Lilly’s New Study on TNG456 and Abemaciclib: A Potential Game-Changer in Cancer Treatment
- Eli Lilly and Bayer’s Promising Prostate Cancer Study: A Potential Game-Changer?
- Eli Lilly announces FDA approval of label update for Kisunla